Asia accounts for nearly half of the world's new cancer cases each year, posing a massive health challenge amid aging populations and rising costs.
New liquid biopsy technologies combined with artificial intelligence are enabling simple blood draws to detect cancer early, shifting the odds for millions.
Trailblazing Blood Tests Lead the Way
Singapore-based biotech firm MiRXES has pioneered GASTROClear, the world's first approved molecular blood test for early gastric cancer using microRNA biomarkers.
GASTROClear gained approval from China's NMPA in October 2025 following a large trial with over 9,000 subjects, targeting high-risk adults aged 45 to 74.
In Vietnam, the SPOT-MAS test screens for multiple cancers including liver, breast, and lung from one blood sample, boasting high sensitivity in low-resource settings.
AI Supercharges Diagnostics
Artificial intelligence analyzes complex oncology data, improving detection accuracy and speeding up genomic processing from weeks to days.
China's AI healthcare market reached 106 billion yuan in 2024, with over 150 approved AI devices fueling pilots in hundreds of hospitals nationwide.
Singapore's initiatives like the SIMFONI program and partnerships such as Curie Oncology with Oncoshot are matching patients to trials faster than ever.
Why This Matters for Asia's Future
Early detection through these tests could boost five-year survival rates dramatically, from under 25% in late stages to over 90% when caught early.
Beyond lives saved, these innovations slash treatment costs that often exceed average incomes, easing family burdens and national healthcare systems.
A non-obvious edge: Asia's diverse data pools are training AI models uniquely suited to regional genetics, potentially leapfrogging Western competitors in precision medicine.
Challenges like regulatory harmonization persist, but with national programs ramping up, population-scale screening could become reality by 2030.
Maria Lourdes
